Botulinum Therapy for Chronic Migraine
Keywords:
Botulinum; Therapy; Chronic MigraineAbstract
No Abstract
References
1. The International Classification of Headache Disorders: 2nd edition. Cephaข-
lalgia 2004; 24(Suppl 1): 1-160.
2. Ashkenazi A. Botulinum toxin type A for chronic migraine. Curr Neurol
Neurosci Rep. 2010 Mar;10(2):140-6.
3. Olesen J, Bousser MG, Diener HC, Dodick D, First M, Goadsby PJ,
et al. New appendix criteria open for a broader concept of chronic migraine.
Cephalalgia. 2006 Jun;26(6):742-6.
4. Natoli JL, Manack A, Dean B, Butler Q, Turkel CC, Stovner L, et al.
Global prevalence of chronic migraine: a systematic review. Cephalalgia.
2010 May;30(5):599-609.
5. Diener HC, Holle D, Dodick D. Treatmet of chronic migraine. Curr Pain
Headache Rep. 2011 Feb;15(1):64-9.
6. Bigal ME, Serrano D, Reed M, Lipton RB. Chronic migraine in the
population: burden, diagnosis, and satisfaction with treatment. Neurology.
2008 Aug 19;71(8):559-66.
7. Mathew NT. The prophylactic treatment of chronic daily headache. Headache.
2006 Nov-Dec;46(10):1552-64.
8. Silberstein SD, Marmura MJ, Shaw J, Yu S. Headache prophylaxis with
BoNTA: patient characteristics. Headache. 2010 Jan;50(1):63-70.
9. Gobel H. Botulinum toxin in migraine prophylaxis. J Neurol 2004; 251
(suppl 1): 8-11.
10. Cady R, Schreiber C. Botulinum toxin type A as migraine preventive treatment
in patients previously failing oral prophylactic treatment due to
compliance issues. Headache. 2008 Jun;48(6):900-13.
11. Mathew NT. Pathophysiology of chronic migraine and mode of action
of preventive medications. Headache. 2011 Jul-Aug;51 Suppl 2:84-92.
12. Valfrè W, Rainero I, Bergui M, Pinessi L. Voxel-based morphometry
reveals gray matter abnormalities in migraine. Headache. 2008 Jan;48(1):
109-17.
13. Welch KM, Nagesh V, Aurora SK, Gelman N. Periaqueductal gray matter
dysfunction in migraine: cause or the burden of illness? Headache. 2001
Jul-Aug;41(7):629-37.
14. Aurora SK, Barrodale PM, Tipton RL, Khodavirdi A. Brainstem dysfunction
in chronic migraine as evidenced by neurophysiological and
positron emission tomography studies. Headache. 2007 Jul-Aug;47(7):
996-1003
15. Prescot A, Becerra L, Pendse G, Tully S, Jensen E, Hargreaves R, et al.
Excitatory neurotransmitters in brain regions in interictal migraine patients.
Mol Pain. 2009 Jun 30;5:34.
16. Aoki KR. Pharmacology and immunology of botulinum toxin serotypes.
J Neurol. 2001 Apr;248 Suppl 1:3-10.
17. Brin MF. Botulinum toxin: chemistry, pharmacology, toxicity, and immunology.
Muscle Nerve 1997; 6: 146-68.
18. Jankovic J. Botulinum toxin in clinical practice. J Neurol Neurosurg
Psychiatry. 2004 Jul;75(7):951-7.
19. Brin MF, Fahn S, Moskowitz C, Friedman A, Shale HM, Greene PE, et al.
Localized injections of botulinum toxin for the treatment of focal dystonia
and hemifacial spasm. Mov Disord. 1987;2(4):237-54.
20. Binder WJ, Brin MF, Blitzer A, Schoenrock LD, Pogoda JM. Botulinum
toxin type A for treatment of migraine headaches: an open-label study.
Otolaryngol Head Neck Surg. 2000 Dec;123(6):669-76.
21. Cui M, Khanijou S, Rubino J, Aoki KR. Subcutaneous administration
of botulinum toxin A reduces formalin-induced pain. Pain. 2004 Jan;107
(1-2):125-33.
22. Welch MJ, Purkiss JR, Foster KA. Sensitivity of embryonic rat dorsal
root ganglia neuron to Clostridium botulinum neurotoxin. Toxicon. 2000
Feb;38(2):245-58.
23. Durham PL, Cady R. Regulation of calcitonin gene-related peptide secretion
from trigeminal nerve cells by botulinum toxin type A: implication for
migraine therapy. Headache. 2004 Jan;44(1):35-42.
24. Aoki KR. Review of a proposed mechanism for the antinociceptive action
of botulinum toxin type A. Neurotoxicology. 2005 Oct;26(5):785-93.
25. Shuhendler AJ, Lee S, Siu M, Ondovcik S, Lam K, Alabdullatif A, et al.
Efficacy of botulinum toxin type A for the prophylaxis of episodic migraine
headache: a meta-analysis of randomized, double-blind, placebo-controlled
trials. Pharmacotherapy. 2009 Jul;29(7):784-91.
26. Gobel H, Heinze A, Zumbroich V, et al. Treatment of coexisting migraine
and chronic tension-type headache with botulinum toxin A: a double
blind placebo-controlled study. Cephalalgia 2003; 23: 690.
27. Freitag FG, Diamond S, Diamond M, Urban G. Botulinum toxin type
A in the treatment of chronic migraine without medication overuse. Headache.
2008 Feb;48(2):201-9.
28. Aurora SK, Dodick DW, Turkel CC, DeGryse RE, Silberstein SD, et al.
Onabotulinumtoxin A for treatment of chronic migraine: results from the
double-blind, randomized, placebo-controlled phase of the PREEMPT 1
trial. Cephalalgia. 2010 Jul;30(7):793-803.
29. Diener HC, Dodick DW, Aurora SK, Turkel CC, DeGryse RE, Lipton
RB, et al. Onabotulinumtoxin A for treatment of chronic migraine: results
from the double-blind, randomized, placebo-controlled phase of the
PREEMPT 2 trial. Cephalalgia. 2010 Jul;30(7):804-14.
30. Cady RK, Schreiber CP, Porter JA, Blumenfeld AM, Farmer KU. A multicenter
double-blind pilot comparison of onabotulinumtoxin A and topiramate
for the prophylactic treatment of chronic migraine. Headache. 2011
Jan;51(1):21-32.
31. Mauskop A. The use of botulinum toxin in the treatment of headaches.
Pain Physician. 2004 Jul;7(3):377-87.
32. Argov Z, Mastaglia FL. Disorder of neuromuscular transmission caused
by drugs. N Engl J Med. 1979 Aug 23;301(8):409-13.
lalgia 2004; 24(Suppl 1): 1-160.
2. Ashkenazi A. Botulinum toxin type A for chronic migraine. Curr Neurol
Neurosci Rep. 2010 Mar;10(2):140-6.
3. Olesen J, Bousser MG, Diener HC, Dodick D, First M, Goadsby PJ,
et al. New appendix criteria open for a broader concept of chronic migraine.
Cephalalgia. 2006 Jun;26(6):742-6.
4. Natoli JL, Manack A, Dean B, Butler Q, Turkel CC, Stovner L, et al.
Global prevalence of chronic migraine: a systematic review. Cephalalgia.
2010 May;30(5):599-609.
5. Diener HC, Holle D, Dodick D. Treatmet of chronic migraine. Curr Pain
Headache Rep. 2011 Feb;15(1):64-9.
6. Bigal ME, Serrano D, Reed M, Lipton RB. Chronic migraine in the
population: burden, diagnosis, and satisfaction with treatment. Neurology.
2008 Aug 19;71(8):559-66.
7. Mathew NT. The prophylactic treatment of chronic daily headache. Headache.
2006 Nov-Dec;46(10):1552-64.
8. Silberstein SD, Marmura MJ, Shaw J, Yu S. Headache prophylaxis with
BoNTA: patient characteristics. Headache. 2010 Jan;50(1):63-70.
9. Gobel H. Botulinum toxin in migraine prophylaxis. J Neurol 2004; 251
(suppl 1): 8-11.
10. Cady R, Schreiber C. Botulinum toxin type A as migraine preventive treatment
in patients previously failing oral prophylactic treatment due to
compliance issues. Headache. 2008 Jun;48(6):900-13.
11. Mathew NT. Pathophysiology of chronic migraine and mode of action
of preventive medications. Headache. 2011 Jul-Aug;51 Suppl 2:84-92.
12. Valfrè W, Rainero I, Bergui M, Pinessi L. Voxel-based morphometry
reveals gray matter abnormalities in migraine. Headache. 2008 Jan;48(1):
109-17.
13. Welch KM, Nagesh V, Aurora SK, Gelman N. Periaqueductal gray matter
dysfunction in migraine: cause or the burden of illness? Headache. 2001
Jul-Aug;41(7):629-37.
14. Aurora SK, Barrodale PM, Tipton RL, Khodavirdi A. Brainstem dysfunction
in chronic migraine as evidenced by neurophysiological and
positron emission tomography studies. Headache. 2007 Jul-Aug;47(7):
996-1003
15. Prescot A, Becerra L, Pendse G, Tully S, Jensen E, Hargreaves R, et al.
Excitatory neurotransmitters in brain regions in interictal migraine patients.
Mol Pain. 2009 Jun 30;5:34.
16. Aoki KR. Pharmacology and immunology of botulinum toxin serotypes.
J Neurol. 2001 Apr;248 Suppl 1:3-10.
17. Brin MF. Botulinum toxin: chemistry, pharmacology, toxicity, and immunology.
Muscle Nerve 1997; 6: 146-68.
18. Jankovic J. Botulinum toxin in clinical practice. J Neurol Neurosurg
Psychiatry. 2004 Jul;75(7):951-7.
19. Brin MF, Fahn S, Moskowitz C, Friedman A, Shale HM, Greene PE, et al.
Localized injections of botulinum toxin for the treatment of focal dystonia
and hemifacial spasm. Mov Disord. 1987;2(4):237-54.
20. Binder WJ, Brin MF, Blitzer A, Schoenrock LD, Pogoda JM. Botulinum
toxin type A for treatment of migraine headaches: an open-label study.
Otolaryngol Head Neck Surg. 2000 Dec;123(6):669-76.
21. Cui M, Khanijou S, Rubino J, Aoki KR. Subcutaneous administration
of botulinum toxin A reduces formalin-induced pain. Pain. 2004 Jan;107
(1-2):125-33.
22. Welch MJ, Purkiss JR, Foster KA. Sensitivity of embryonic rat dorsal
root ganglia neuron to Clostridium botulinum neurotoxin. Toxicon. 2000
Feb;38(2):245-58.
23. Durham PL, Cady R. Regulation of calcitonin gene-related peptide secretion
from trigeminal nerve cells by botulinum toxin type A: implication for
migraine therapy. Headache. 2004 Jan;44(1):35-42.
24. Aoki KR. Review of a proposed mechanism for the antinociceptive action
of botulinum toxin type A. Neurotoxicology. 2005 Oct;26(5):785-93.
25. Shuhendler AJ, Lee S, Siu M, Ondovcik S, Lam K, Alabdullatif A, et al.
Efficacy of botulinum toxin type A for the prophylaxis of episodic migraine
headache: a meta-analysis of randomized, double-blind, placebo-controlled
trials. Pharmacotherapy. 2009 Jul;29(7):784-91.
26. Gobel H, Heinze A, Zumbroich V, et al. Treatment of coexisting migraine
and chronic tension-type headache with botulinum toxin A: a double
blind placebo-controlled study. Cephalalgia 2003; 23: 690.
27. Freitag FG, Diamond S, Diamond M, Urban G. Botulinum toxin type
A in the treatment of chronic migraine without medication overuse. Headache.
2008 Feb;48(2):201-9.
28. Aurora SK, Dodick DW, Turkel CC, DeGryse RE, Silberstein SD, et al.
Onabotulinumtoxin A for treatment of chronic migraine: results from the
double-blind, randomized, placebo-controlled phase of the PREEMPT 1
trial. Cephalalgia. 2010 Jul;30(7):793-803.
29. Diener HC, Dodick DW, Aurora SK, Turkel CC, DeGryse RE, Lipton
RB, et al. Onabotulinumtoxin A for treatment of chronic migraine: results
from the double-blind, randomized, placebo-controlled phase of the
PREEMPT 2 trial. Cephalalgia. 2010 Jul;30(7):804-14.
30. Cady RK, Schreiber CP, Porter JA, Blumenfeld AM, Farmer KU. A multicenter
double-blind pilot comparison of onabotulinumtoxin A and topiramate
for the prophylactic treatment of chronic migraine. Headache. 2011
Jan;51(1):21-32.
31. Mauskop A. The use of botulinum toxin in the treatment of headaches.
Pain Physician. 2004 Jul;7(3):377-87.
32. Argov Z, Mastaglia FL. Disorder of neuromuscular transmission caused
by drugs. N Engl J Med. 1979 Aug 23;301(8):409-13.
Downloads
Published
03-04-2020
How to Cite
Anamnart, C. ., & Poungvarin, N. . (2020). Botulinum Therapy for Chronic Migraine. Siriraj Medical Journal, 63(5), 171–173. Retrieved from https://he02.tci-thaijo.org/index.php/sirirajmedj/article/view/241002
Issue
Section
Special Issue
License
Users are free to share, copy, and redistribute all articles published in the Siriraj Medical Journal (SMJ) in any medium or format as long as you follow the following terms:
- Attribution — You must give appropriate credit, provide a link to the material, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the publisher endorses you or your use.
- NonCommercial — You may not use the material for commercial purposes.
- NoDerivatives — If you remix, transform, or build upon the material, you may not distribute the modified material.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
